Home ›
Entities
› academia
› Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region
Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region
Research article (Cardiovascular Diabetology, 2021) · cited 26× · AI/ML
Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region
Summary
Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region is a scholarly article[1].
Key Facts
Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region. Retrieved May 24, 2026, from https://4ort.xyz/entity/cost-effectiveness-evaluation-of-add-on-dapagliflozin-for-heart-failure-with-reduced-ejection-fraction-from-perspective-
MLA“Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/cost-effectiveness-evaluation-of-add-on-dapagliflozin-for-heart-failure-with-reduced-ejection-fraction-from-perspective-.
BibTeX@misc{4ortxyz_cost-effectiveness-evaluation-of-add-on-dapagliflozin-for-heart-failure-with-reduced-ejection-fraction-from-perspective-_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region}}, year = {2026}, url = {https://4ort.xyz/entity/cost-effectiveness-evaluation-of-add-on-dapagliflozin-for-heart-failure-with-reduced-ejection-fraction-from-perspective-}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region — https://4ort.xyz/entity/cost-effectiveness-evaluation-of-add-on-dapagliflozin-for-heart-failure-with-reduced-ejection-fraction-from-perspective- (retrieved 2026-05-24)
